DREAMM-2: Exploration of BCVA, Ocular Symptoms, and OSDI Questionnaire as Surrogates for Corneal Alterations During Treatment With Belantamab Mafodotin in R/R MM

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: May 12, 2022 Expired: May 11, 2023

Rebecca Gonzalez, PharmD, BCOP, discusses key pharmacy strategies for management of patients with multiple myeloma in this commentary from Clinical Care Options (CCO)

Rebecca Gonzalez, PharmD, BCOP Released: May 6, 2022

PDF resource that serves as a helpful guide for healthcare professionals on BCMA-targeted therapies in multiple myeloma, from Clinical Care Options (CCO)

On-demand webcast on CAR T-cells for patients with hematologic malignancies, from Clinical Care Options (CCO)

Craig Freyer, PharmD, BCOP Andrew Lin, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023